NASDAQ:PDEX Pro-Dex - PDEX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pro-Dex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $17.00 0.00 (0.00%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$16.50▼$17.1150-Day Range$15.29▼$17.7152-Week Range$12.40▼$21.43Volume2,817 shsAverage Volume3,218 shsMarket Capitalization$60.18 millionP/E Ratio16.51Dividend YieldN/APrice Target$30.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Pro-Dex MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside76.5% Upside$30.00 Price TargetShort InterestHealthy0.49% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.88 out of 5 starsMedical Sector740th out of 1,005 stocksSurgical & Medical Instruments Industry72nd out of 102 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $30.00, Pro-Dex has a forecasted upside of 76.5% from its current price of $17.00.Amount of Analyst CoveragePro-Dex has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.49% of the float of Pro-Dex has been sold short.Short Interest Ratio / Days to CoverPro-Dex has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pro-Dex has recently decreased by 2.48%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPro-Dex does not currently pay a dividend.Dividend GrowthPro-Dex does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PDEX. Previous Next 2.7 News and Social Media Coverage News SentimentPro-Dex has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Pro-Dex this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pro-Dex insiders have not sold or bought any company stock.Percentage Held by Insiders42.60% of the stock of Pro-Dex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.49% of the stock of Pro-Dex is held by institutions. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Pro-Dex is 16.51, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 122.68.Price to Earnings Ratio vs. SectorThe P/E ratio of Pro-Dex is 16.51, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 118.74.Price to Book Value per Share RatioPro-Dex has a P/B Ratio of 2.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Pro-Dex (NASDAQ:PDEX) StockPro-Dex, Inc. engages in the design, development and manufacture of rotary drive surgical and dental instruments. The firm specializes in medical devices and services, industrial and scientific, dental and component, repairs and other. Its products include finished medical devices, micro air-motors, dental products, plastic injection molding and torque wrenches. The company was founded on January 26, 1994 and is headquartered in Irvine, CA.Read More Receive PDEX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pro-Dex and its competitors with MarketBeat's FREE daily newsletter. Email Address PDEX Stock News HeadlinesMarch 22, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Pro-Dex (NASDAQ:PDEX)February 27, 2023 | finance.yahoo.comPro-Dex's (NASDAQ:PDEX) Returns On Capital Not Reflecting Well On The BusinessMarch 26, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...February 14, 2023 | finance.yahoo.comPro-Dex, Inc. Discusses 2nd Quarter Results and 2023 Growth Strategy with The Stock Day PodcastFebruary 2, 2023 | msn.comPro-Dex GAAP EPS of $0.24 misses by $0.05, revenue of $11.28M beats by $0.88MFebruary 2, 2023 | finance.yahoo.comPro-Dex, Inc. Announces Fiscal 2023 Second Quarter and Six-Month ResultsJanuary 30, 2023 | seekingalpha.comPro-Dex Is Growing But Expensive Given Its RiskJanuary 20, 2023 | finance.yahoo.comWhy Pro-Dex, Inc. (NASDAQ:PDEX) Could Be Worth WatchingMarch 26, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.January 18, 2023 | reuters.comPDEX.A - | Stock Price & Latest News | ReutersDecember 21, 2022 | finance.yahoo.comPro-Dex (NASDAQ:PDEX) shareholders have earned a 19% CAGR over the last five yearsNovember 25, 2022 | msn.comPro-Dex Earnings Perspective: Return On Invested CapitalNovember 23, 2022 | finance.yahoo.comDeclining Stock and Solid Fundamentals: Is The Market Wrong About Pro-Dex, Inc. (NASDAQ:PDEX)?November 9, 2022 | finance.yahoo.comPro-Dex First Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsNovember 4, 2022 | finance.yahoo.comPro-Dex, Inc. Announces Fiscal 2023 First Quarter ResultsOctober 22, 2022 | finance.yahoo.comQuite a few insiders invested in Pro-Dex, Inc. (NASDAQ:PDEX) last year which is positive news for shareholdersOctober 17, 2022 | nasdaq.comPro-Dex (NASDAQ:PDEX) May Have Issues Allocating Its CapitalSeptember 29, 2022 | finance.yahoo.comPro-Dex, Inc. Discusses Record-Breaking 4th Quarter Results and Year-Over-Year Growth with The Stock Day PodcastSeptember 26, 2022 | seekingalpha.comPro-Dex: Growth Trends In Earnings, Return On Investment ContractingSeptember 20, 2022 | finance.yahoo.comSome Investors May Be Worried About Pro-Dex's (NASDAQ:PDEX) Returns On CapitalAugust 25, 2022 | finance.yahoo.comPro-Dex, Inc. Announces Fiscal 2022 Fourth Quarter And Full-Year ResultsAugust 6, 2022 | reuters.comPro-Dex IncJuly 31, 2022 | nasdaq.comHere's Why Pro-Dex (NASDAQ:PDEX) Has A Meaningful Debt BurdenJuly 14, 2022 | finance.yahoo.comPro-Dex (NASDAQ:PDEX) shareholders have earned a 21% CAGR over the last five yearsJune 14, 2022 | finance.yahoo.comPro-Dex, Inc. (NASDAQ:PDEX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?June 6, 2022 | finance.yahoo.comPro-Dex, Inc. Discusses 2022 Goals and Third Quarter Results with The Stock Day PodcastMay 15, 2022 | finance.yahoo.comA number of insiders bought Pro-Dex, Inc. (NASDAQ:PDEX) stock last year, which is great news for shareholdersSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PDEX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pro-Dex and its competitors with MarketBeat's FREE daily newsletter. Email Address PDEX Company Calendar Last Earnings2/02/2023Today3/25/2023Next Earnings (Estimated)5/04/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PDEX CUSIPN/A CIK788920 Webwww.pro-dex.com Phone(949) 769-3200Fax949-769-3281Employees117Year FoundedN/APrice Target and Rating Average Stock Price Forecast$30.00 High Stock Price Forecast$30.00 Low Stock Price Forecast$30.00 Forecasted Upside/Downside+76.5%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)$1.03 Trailing P/E Ratio16.51 Forward P/E RatioN/A P/E GrowthN/ANet Income$3.86 million Net Margins8.64% Pretax Margin10.38% Return on Equity16.12% Return on Assets8.19% Debt Debt-to-Equity Ratio0.39 Current Ratio2.69 Quick Ratio1.39 Sales & Book Value Annual Sales$42.04 million Price / Sales1.43 Cash Flow$1.30 per share Price / Cash Flow13.05 Book Value$6.54 per share Price / Book2.60Miscellaneous Outstanding Shares3,540,000Free Float2,034,000Market Cap$60.18 million OptionableNot Optionable Beta0.99 Key ExecutivesRichard Lee van KirkPresident, Chief Executive Officer, COO & DirectorAlisha K. CharltonChief Financial Officer & SecretaryKey CompetitorsRetractable TechnologiesNYSE:RVPLucid DiagnosticsNASDAQ:LUCDIsorayNYSE:ISRLyra TherapeuticsNASDAQ:LYRACo-DiagnosticsNASDAQ:CODXView All CompetitorsInstitutional OwnershipAdvisor Group Holdings Inc.Sold 1,600 shares on 2/10/2023Ownership: 0.467%Dimensional Fund Advisors LPBought 625 shares on 2/9/2023Ownership: 1.658%View All Institutional Transactions PDEX Stock - Frequently Asked Questions What is Pro-Dex's stock price forecast for 2023? 0 Wall Street research analysts have issued 12 month price targets for Pro-Dex's stock. Their PDEX share price forecasts range from $30.00 to $30.00. On average, they anticipate the company's share price to reach $30.00 in the next twelve months. This suggests a possible upside of 76.5% from the stock's current price. View analysts price targets for PDEX or view top-rated stocks among Wall Street analysts. How have PDEX shares performed in 2023? Pro-Dex's stock was trading at $15.90 at the start of the year. Since then, PDEX stock has increased by 6.9% and is now trading at $17.00. View the best growth stocks for 2023 here. When is Pro-Dex's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our PDEX earnings forecast. How were Pro-Dex's earnings last quarter? Pro-Dex, Inc. (NASDAQ:PDEX) posted its earnings results on Thursday, February, 2nd. The medical instruments supplier reported $0.24 EPS for the quarter. The medical instruments supplier had revenue of $11.28 million for the quarter. Pro-Dex had a net margin of 8.64% and a trailing twelve-month return on equity of 16.12%. What is Michael J. Berthelot's approval rating as Pro-Dex's CEO? 3 employees have rated Pro-Dex Chief Executive Officer Michael J. Berthelot on Glassdoor.com. Michael J. Berthelot has an approval rating of 85% among the company's employees. What other stocks do shareholders of Pro-Dex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pro-Dex investors own include KEMET (KEM), NVIDIA (NVDA), Enterprise Products Partners (EPD), Micron Technology (MU), AT&T (T), AbbVie (ABBV), Alibaba Group (BABA), Bank of America (BAC), Marvell Technology (MRVL) and UnitedHealth Group (UNH). What is Pro-Dex's stock symbol? Pro-Dex trades on the NASDAQ under the ticker symbol "PDEX." Who are Pro-Dex's major shareholders? Pro-Dex's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (1.66%) and Advisor Group Holdings Inc. (0.47%). Insiders that own company stock include Alisha Charlton, Katrina Marie Kramer Philp, Kirk Richard Lee Van Jr, Nicholas John Swenson, Raymond E Cabillot and William James Farrell III. View institutional ownership trends. How do I buy shares of Pro-Dex? Shares of PDEX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pro-Dex's stock price today? One share of PDEX stock can currently be purchased for approximately $17.00. How much money does Pro-Dex make? Pro-Dex (NASDAQ:PDEX) has a market capitalization of $60.18 million and generates $42.04 million in revenue each year. The medical instruments supplier earns $3.86 million in net income (profit) each year or $1.03 on an earnings per share basis. How many employees does Pro-Dex have? The company employs 117 workers across the globe. How can I contact Pro-Dex? Pro-Dex's mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The official website for the company is www.pro-dex.com. The medical instruments supplier can be reached via phone at (949) 769-3200, via email at investor.relations@pro-dex.com, or via fax at 949-769-3281. This page (NASDAQ:PDEX) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.